Cancer Stem Cell Markers Are Associated With Distant Hematogenous Liver Metastases But Not With Peritoneal Carcinomatosis in Colorectal Cancer

REFERENCES

• Desch CE, Benson AB, 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23(33):8512–8519.
   PubMed Web of Science ®Google Scholar
• Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011;128(11):2717–2725.
   PubMed Web of Science ®Google Scholar
• Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99(5):699–705.
   PubMed Web of Science ®Google Scholar
• Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89(12):1545–1550.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12(1):65–71.
   PubMed Web of Science ®Google Scholar
• van Gestel YR, Thomassen I, Lemmens VE, Pruijt JF, van Herk-Sukel MP, Rutten HJ, Creemers GJ, de Hingh IH. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 2013.
   PubMed Web of Science ®Google Scholar
• Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum 2013;56(12):1373–1380.
   PubMed Web of Science ®Google Scholar
• Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007;19(2):150–158.
   PubMed Web of Science ®Google Scholar
• Brabletz S, Schmalhofer O, Brabletz T. Gastrointestinal stem cells in development and cancer. J Pathol 2009;217(2):307–317.
   PubMed Web of Science ®Google Scholar
• Jung A, Brabletz T, Kirchner T. The migrating cancer stem cells model–a conceptual explanation of malignant tumour progression. Ernst Schering Found Symp Proc 2006;(5):109–124.
   PubMedGoogle Scholar
• de Lau W, Barker N, Clevers H. WNT signaling in the normal intestine and colorectal cancer. Front Biosci 2007;12:471–491.
   PubMed Web of Science ®Google Scholar
• Horst D, Reu S, Kriegl L, Engel J, Kirchner T, Jung A. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer 2009;115(10):2063–2070.
   PubMed Web of Science ®Google Scholar
• Horst D, Kriegl L, Engel J, Jung A, Kirchner T. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 2009;45(11):2034–2040.
   PubMed Web of Science ®Google Scholar
• Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27(8):844–850.
   PubMed Web of Science ®Google Scholar
• Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99(8):1285–1289.
   PubMed Web of Science ®Google Scholar
• Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219(4):427–434.
   PubMed Web of Science ®Google Scholar
• Neumann J, Horst D, Kriegl L, Maatz S, Engel J, Jung A, Kirchner T. A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer. Histopathology 2012;60(3):416–426.
   PubMed Web of Science ®Google Scholar
• Bosman F, Carneiro F, Hruban R, Theise N. WHO Classification of Tumours of the Digestive System. In. Lyon: International Agency for Research on Cancer (IARC); 2010.
   Google Scholar
• Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 2009.
   Google Scholar
• Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5(9):744–749.
   PubMed Web of Science ®Google Scholar
• Fernandez JC, Vizoso FJ, Corte MD, Gava RR, Corte MG, Suarez JP, Garcia-Muniz JL, Garcia-Moran M. CD44s expression in resectable colorectal carcinomas and surrounding mucosa. Cancer Invest 2004;22(6):878–885.
   PubMed Web of Science ®Google Scholar
• Huh JW, Kim HR, Kim YJ, Lee JH, Park YS, Cho SH, Joo JK. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 2009;59(4):241–246.
   PubMed Web of Science ®Google Scholar
• Ichikawa W. Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer. Pathobiology 1994;62(4):172–179.
   PubMed Web of Science ®Google Scholar
• Visca P, Del Nonno F, Botti C, Marandino F, Sebastiani V, Di Tondo U, Donnorso RP, Trombetta G, Filippi S, Alo PL. Role and prognostic significance of CD44s expression in colorectal cancer. Anticancer Res 2002;22(5):2671–2675.
   PubMed Web of Science ®Google Scholar
• Ylagan LR, Scholes J, Demopoulos R. Cd44: a marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 2000;124(2):212–215.
   PubMed Web of Science ®Google Scholar
• Heider KH, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P, Pals ST. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993;120(1):227–233.
   PubMed Web of Science ®Google Scholar
• Gunthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993;184:47–63.
   PubMedGoogle Scholar